Clinical Trials Browser

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT04195633 2026-02-27

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Phase 2 Recruiting

60 enrolled

LymphoidMyeloidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04684368 2026-02-24

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

Phase 2 Recruiting

160 enrolled

Choriocarcinoma, Teratoma, Carcinoma, Embryonal

NCT06207799 2026-02-19

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Phase 2 Recruiting

40 enrolled

Plasma cell

Multiple Myeloma

NCT07188090 2025-11-28

HSCT

Phase 2 Recruiting

100 enrolled

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT02143830 2025-11-12

RAFA

Phase 2 Recruiting

70 enrolled

Classical hematologyMyeloidOther hematologic neoplasm

Cytopenia, Anemia, Refractory, with Excess of Blasts, Fanconi Anemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03125642 2025-11-04

Auto Stem Cell Transplant for Lymphoma Patients

Phase 2 Recruiting

150 enrolled

LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02605421 2025-10-21

Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

Phase 2 Recruiting

12 enrolled

CNS

Neuroblastoma

NCT06649851 2025-09-25

G-CSF After Chemo-radiation in Patients With Glioblastoma

Phase 2 Recruiting

60 enrolled

CNS

Glioblastoma

NCT04050280 2025-05-01

CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

Phase 2 Recruiting

39 enrolled

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT05603884 2025-02-19

VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Phase 2 Recruiting

66 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06741722 2024-12-27

Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML

Phase 2 Recruiting

20 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06742463 2024-12-19

VHAG in Treating R/R T-ALL/LBL

Phase 2 Recruiting

50 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06316960 2024-08-22

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

Phase 2 Recruiting

50 enrolled

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Clinical Trials

GM-CSF With Post-Transplant Cyclophosphamide

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial

BCL2i CLAG-M in R/R Acute Myeloid Leukemia

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

MORE

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

HSCT

RAFA

Auto Stem Cell Transplant for Lymphoma Patients

Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

G-CSF After Chemo-radiation in Patients With Glioblastoma

CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML

VHAG in Treating R/R T-ALL/LBL

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation